Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use is considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. Compulsive redosing has been reported, and cravings may occur if use is suddenly stopped.
Withdrawal effects may occur when dependence has developed and use is suddenly stopped, though specific physical withdrawal symptoms are not well characterized for this compound.
The exact human toxic dosage is unknown due to the limited history of human use and lack of formal toxicological studies.
| Species | Route | Value |
|---|---|---|
| mouse | IP | 100 mg/kg |
Acute cardiovascular stimulation including increased heart rate, elevated blood pressure, abnormal heartbeat, and vasoconstriction occurs during intoxication; long-term cardiovascular effects have not been studied in any scientific context.
Abuse of amphetamine-class compounds at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Reviews of amphetamine-induced psychosis indicate that approximately 5-15% of affected users may not fully recover, though antipsychotic medications are effective for acute episodes.
Seizures are listed as a possible adverse effect, though specific incidence data for 2-FA is not available. Risk may be elevated in combination with other seizure-threshold-lowering substances.
2-Fluoroamphetamine emerged on the online research chemical market during the 2010s as part of a broader wave of fluorinated amphetamine derivatives. This family of compounds includes 2-FMA, 3-FA, 3-FEA, and 4-FA, which are positional isomers differing in the placement of the fluorine atom on the…
Considered a Schedule I controlled substance as an analogue of amphetamine under Canadian drug scheduling legislation.
Listed in the government decree on substances, preparations, and plants considered to be narcotic drugs, making possession and distribution illegal.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.
Controlled as a Schedule 3 substance due to classification as an amphetamine analogue under New Zealand drug law.
Classified as a controlled drug. Possession, production, supply, and importation are all prohibited under Turkish law.
May be treated as a Schedule II controlled substance under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption, as it is considered substantially similar to amphetamine. Not explicitly scheduled on its own.
Specifically controlled as of October 2015 under Chinese narcotics regulations.
As of December 2024, not explicitly scheduled under French law. Possession is not specifically prohibited but the substance operates in a legal grey area.
Currently not a controlled substance, though it falls within a substance category that may be scheduled under recently enacted New Psychoactive Substances legislation.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled as a Class A substance under the amphetamine analogue clause of the Misuse of Drugs Act 1971. Class A classification carries the most severe penalties under UK drug law.
21 sources cited